News >

Adjuvant Options Expand in HER2+ Breast Cancer, But Questions Remain

Kristi Rosa
Published: Thursday, Nov 15, 2018

Vik Gorantla, MD

Vik Gorantla, MD
The outlook for HER2-positive breast cancer has significantly improved over the past few years, with the emergence of targeted therapies that have been shown to vastly improve patient outcomes. Moreover, recent FDA approvals in the adjuvant setting have added to the armamentarium, explained Vik Gorantla, MD.

“Trastuzumab really changed the landscape of treatment for patients with HER2-positive breast cancer. We have done well in this patient population, but now, we want to see if we can do better,” Vik Gorantla, MD, said. “Pertuzumab has been approved in the metastatic setting and in the neoadjuvant setting, so logically, it makes sense to see if we can use it in the adjuvant setting to get even better results. Can we do better?”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication